Antiphospholipid Syndrome
Clinical Snapshot
Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia in which circulating antiphospholipid antibodies increase the risk of both arterial and venous thrombosis and cause a distinct pattern of pregnancy morbidity — recurrent early miscarriage, later fetal loss, or placental-insufficiency-related complications such as severe preeclampsia and intrauterine growth restriction.[1] The diagnosis is never made from a single positive antibody test: it requires at least 1 qualifying clinical event (a confirmed thrombosis, or one of the defined pregnancy-morbidity patterns) together with a persistently positive antiphospholipid antibody result — lupus anticoagulant, anticardiolipin antibody, or anti-beta-2-glycoprotein I antibody — confirmed on 2 separate occasions at least 12 weeks apart.[1] APS occurs either alone (primary APS) or alongside another autoimmune disease, most often systemic lupus erythematosus (secondary APS) — see the Systemic Lupus Erythematosus chapter for the SLE-specific overlap and its background hydroxychloroquine therapy.[2] The single highest-value pharmacology point in this chapter is that warfarin, not a direct oral anticoagulant (DOAC), is the guideline-recommended standard of care for APS-associated thrombosis — randomized trial evidence shows a DOAC performs worse than warfarin in this specific population, especially triple-positive APS, and current guidance recommends against using a DOAC here even though DOACs are preferred first-line therapy for most other causes of venous thromboembolism.[3][2]
Recognize the Condition
Clinical domains of APS
Venous thrombosis
Deep vein thrombosis and pulmonary embolism are the most common thrombotic presentation, clinically indistinguishable at the bedside from any other cause of VTE — the antibody profile is what identifies APS as the underlying cause.
Arterial thrombosis
Ischemic stroke and transient ischemic attack are the most common arterial events; myocardial infarction and peripheral arterial occlusion also occur. Arterial APS carries a higher recurrence risk than venous APS and is managed with a higher anticoagulation intensity (see Choose Initial Treatment).
Microvascular and organ-specific
Livedo reticularis (a persistent, lace-like mottled skin pattern), APS nephropathy (thrombotic microangiopathy of the renal vasculature presenting with hypertension and proteinuria), and less commonly pulmonary hemorrhage, myocardial microthrombosis, and adrenal hemorrhage or infarction.
Obstetric morbidity
Three or more unexplained consecutive miscarriages before 10 weeks' gestation; 1 or more unexplained deaths of a morphologically normal fetus at or after 10 weeks; or a premature birth before 34 weeks due to eclampsia, severe preeclampsia, or recognized placental insufficiency. This pattern can occur with or without any personal history of thrombosis — "obstetric APS" is a distinct clinical phenotype with its own management pathway (see Choose Initial Treatment and Special Populations).
Hematologic
Thrombocytopenia (usually mild-to-moderate, and not itself a reason to withhold anticoagulation in a patient with a genuine thrombotic indication) and, less commonly, autoimmune hemolytic anemia.
Cardiac valve disease
Libman-Sacks endocarditis — sterile valve thickening and vegetations, most often affecting the mitral valve — can be an embolic source and is often found alongside SLE-associated APS.
A rare, distinct, and rapidly life-threatening variant — catastrophic APS — produces thrombosis in 3 or more organs developing over days rather than the single-event pattern typical of standard APS; see Red Flags & Refer.
Risk Factors
- Systemic lupus erythematosus or another autoimmune connective tissue disease (secondary APS) — see the Systemic Lupus Erythematosus chapter for the overlap.
- Female sex, particularly during reproductive years.
- A triple-positive antibody profile (lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoprotein I all positive) — the single strongest predictor of future thrombotic and obstetric events.
- A personal history of thrombosis or pregnancy morbidity consistent with APS.
- Conventional prothrombotic risk factors that compound APS-related risk rather than replacing it as the explanation — smoking, obesity, immobilization, recent surgery, and estrogen-containing contraception or hormone therapy (see Non-Pharmacologic Treatment).
- Pregnancy and the postpartum period.
- Family history of APS or another autoimmune disease.
- Rarely, transient antiphospholipid antibody positivity associated with certain infections or medications — distinguished from true APS by the absence of a qualifying clinical event and by non-persistence on repeat testing.
Red Flags & Refer
Escalate immediately — do not manage any of the following as routine outpatient care:
- Catastrophic APS — thrombosis affecting 3 or more organs, developing over days, with laboratory confirmation of antiphospholipid antibodies — a rare but life-threatening emergency with a high mortality rate; requires immediate hospitalization or ICU-level care and combination therapy (see Choose Initial Treatment).[2]
- New signs of stroke, TIA, or myocardial infarction in a patient with known or suspected APS.
- New signs or symptoms of DVT or PE (see the Venous Thromboembolism chapter for the diagnostic pathway).
- Severe preeclampsia, HELLP syndrome, or signs of placental insufficiency in a pregnant patient with known or suspected APS — refer urgently to a high-risk obstetric team.
- Major or life-threatening bleeding in any patient on anticoagulation for APS.
- New or worsening thrombocytopenia, particularly if severe or accompanied by microangiopathic hemolysis — evaluate for catastrophic APS or a thrombotic microangiopathy rather than attributing it to APS alone.
- Recurrent thrombosis despite adequately dosed, adherent anticoagulation — a genuine treatment-failure presentation (see Treatment Failure & Next Step), not something to manage by simply continuing the same regimen.
Assessment & Diagnosis
Diagnostic criteria (international consensus / revised Sapporo)
APS is diagnosed clinically using the international consensus (revised Sapporo) criteria: at least 1 clinical criterion plus at least 1 laboratory criterion, with the laboratory result confirmed positive on 2 or more occasions at least 12 weeks apart.[1]
| Category | Qualifying criteria |
|---|---|
| Clinical — vascular thrombosis | 1 or more objectively confirmed episodes of arterial, venous, or small-vessel thrombosis in any tissue or organ (imaging or histopathology confirmation required; histopathology must show thrombosis without significant vessel-wall inflammation). |
| Clinical — pregnancy morbidity | 1 or more unexplained deaths of a morphologically normal fetus at or after the 10th week of gestation; OR 1 or more premature births of a morphologically normal neonate before the 34th week due to eclampsia, severe preeclampsia, or recognized placental insufficiency; OR 3 or more unexplained consecutive spontaneous miscarriages before the 10th week, with maternal anatomic/hormonal and parental chromosomal causes excluded. |
| Laboratory — lupus anticoagulant | Present in plasma, on 2 or more occasions at least 12 weeks apart, detected per current ISTH guidance. |
| Laboratory — anticardiolipin antibody | IgG and/or IgM present at medium-to-high titre, on 2 or more occasions at least 12 weeks apart. |
| Laboratory — anti-beta-2-glycoprotein I antibody | IgG and/or IgM present at a titre above the 99th percentile, on 2 or more occasions at least 12 weeks apart. |
Antibody testing caveats
Order all 3 tests together whenever possible — lupus anticoagulant, anticardiolipin (IgG and IgM), and anti-beta-2-glycoprotein I (IgG and IgM) — since the antibody profile itself is a risk-stratification tool, not just a yes/no diagnostic gate (see below). Avoid testing during an acute thrombotic event or acute illness where possible: transient, clinically insignificant antibody positivity can occur around acute thrombosis, and a result obtained during the acute event should be confirmed with repeat testing once the patient has recovered, in addition to the mandatory 12-week repeat. Anticoagulation can interfere with lupus anticoagulant assays — heparin and warfarin both affect clot-based testing, and a DOAC can produce a false-positive lupus anticoagulant result; involve the coagulation laboratory before ordering, or time testing to a period off interfering anticoagulation where clinically feasible.
Risk stratification: triple positivity
Patients positive for all 3 antibody types — lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoprotein I — are classified as triple-positive and carry the highest risk of both thrombotic recurrence and treatment failure with a DOAC; this profile is central to the anticoagulant-selection decision in Choose Initial Treatment.[2][3]
Primary versus secondary APS
APS occurring in isolation is termed primary APS; APS occurring alongside another autoimmune disease — most often systemic lupus erythematosus, and less often another connective tissue disease — is termed secondary APS. Screen every newly diagnosed APS patient for SLE, and vice versa (see the Systemic Lupus Erythematosus chapter), since the distinction changes the overall care plan (background hydroxychloroquine, SLE-specific monitoring) even though the anticoagulation approach to a given thrombotic or obstetric event is the same either way.
2023 ACR/EULAR classification criteria
A newer, more specific classification system — requiring a qualifying clinical event plus at least 1 positive antibody test within 3 years, then an additive weighted point score across 6 clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular disease, obstetric morbidity, cardiac valve disease, and hematologic/thrombocytopenia) and 2 laboratory domains (lupus anticoagulant, and solid-phase anticardiolipin/anti-beta-2-glycoprotein I testing weighted by titre) — classifies a patient as having APS once both the clinical and laboratory domains individually reach at least 3 points.[4] It was developed primarily to create a more specific cohort for research and clinical trials (specificity 99% versus 86% for the original criteria, at some cost to sensitivity), and its per-item point weighting requires the full published criteria set rather than a simple flat point-sum, so it is presented here as a teaching reference rather than an interactive calculator — the clinical-plus-persistent-antibody framework above remains what is used for everyday bedside diagnosis.[4]
Catastrophic APS
A separate, rare, rapidly progressive variant defined by thrombosis affecting 3 or more organs, developing over days (rather than the single-event pattern typical of standard APS), with laboratory confirmation of antiphospholipid antibodies and, where obtained, histopathological confirmation of small-vessel occlusion — mortality is high without immediate recognition and treatment (see Red Flags & Refer and Choose Initial Treatment).[2]
Treatment Targets
- Prevent first and recurrent thrombosis, matched to the vascular bed (venous versus arterial) and antibody risk profile.
- Support a successful pregnancy and live birth in obstetric APS.
- Recognize and treat catastrophic APS immediately when it occurs.
- Minimize bleeding risk from anticoagulation itself.
- Manage the SLE overlap and shared cardiovascular risk factors in secondary APS.
- Avoid iatrogenic harm — most importantly, avoid a direct oral anticoagulant as the choice for APS-associated thrombosis.
Choose Initial Treatment
The DOAC rule
Avoid direct oral anticoagulants (rivaroxaban, apixaban, dabigatran, edoxaban) for APS-associated thrombosis — a randomized trial in triple-positive, high-risk APS was stopped early because rivaroxaban produced significantly more thromboembolic events than warfarin (12% versus 0% over a mean follow-up of about 19 months), with no bleeding advantage to offset it.[3] Current guidance recommends against a DOAC for APS-associated thrombosis generally, and specifically advises against DOAC use in triple-positive APS and in arterial APS.[2] Warfarin (a vitamin K antagonist) is the guideline-recommended standard of care for APS-associated thrombosis, even though a DOAC is preferred first-line therapy for most other causes of venous thromboembolism (see the Venous Thromboembolism chapter) — do not extrapolate that general preference to a patient with APS.
Antibody-positive, no prior thrombotic or obstetric event
Primary thromboprophylaxis low-dose ASA, particularly with a high-risk profile (triple positivity, or coexisting SLE); some specialists add hydroxychloroquine, which carries an antithrombotic benefit independent of its immunomodulatory effect.[2]
First venous thrombosis
Indefinite warfarin, target INR 2-3 — not a DOAC.[2]
First arterial thrombosis
Indefinite warfarin, target INR 2-3 or a higher target of INR 3-4, individualized against the patient's bleeding risk; some specialists instead add low-dose ASA to warfarin at the standard 2-3 target rather than routinely using the higher INR range — not a DOAC.[2]
Recurrent thrombosis despite adequate warfarin therapy
Intensify confirm adherence and confirm the INR has genuinely been in the therapeutic range over time (not just checked once), then consider adding low-dose ASA, raising the INR target to 3-4, or switching to therapeutic-dose LMWH.[2]
Obstetric APS
Low-dose ASA plus prophylactic-dose heparin throughout pregnancy — start low-dose ASA before or in early pregnancy, add prophylactic-dose LMWH (or unfractionated heparin) once pregnancy is confirmed, and continue both through delivery; the combination improves live birth rate and reduces preeclampsia risk compared with ASA alone in women with prior pregnancy morbidity.[2][5] Warfarin is teratogenic and contraindicated throughout pregnancy — see Special Populations for the conception-planning and thrombotic-APS-in-pregnancy pathway.
Catastrophic APS
Emergency combination therapy therapeutic-dose anticoagulation (heparin) plus a corticosteroid plus plasma exchange or IVIG, together with treatment of any precipitating factor (infection is the most common trigger) — do not treat with anticoagulation alone.[2]
Non-Pharmacologic Treatment
- Smoking cessation — an independent, modifiable thrombosis risk factor that compounds APS-related risk.
- Avoid estrogen-containing contraception and estrogen-containing hormone therapy in anyone with a positive antiphospholipid antibody profile, regardless of whether they meet full APS criteria — use a non-hormonal method or a progestin-only method instead.
- Aggressively manage conventional cardiovascular risk factors — blood pressure, lipids, glucose, and weight — since these compound thrombotic risk on top of APS itself.
- Avoid unnecessary prolonged immobilization; use mechanical and/or pharmacologic VTE prophylaxis around any hospitalization or surgery, planned well in advance with the treating specialist for anyone on chronic warfarin who needs perioperative bridging.
- Patient education: medical alert identification stating the APS diagnosis and current anticoagulant, and a clear individualized action plan for suspected new thrombosis or, in a pregnant patient, an obstetric emergency.
- Early ambulation after any thrombotic event, as tolerated, once anticoagulation is therapeutic.
- For women of reproductive age: discuss family planning and warfarin's teratogenicity proactively, well before an unplanned pregnancy occurs (see Special Populations).
Special Populations
Pregnancy
Obstetric APS (pregnancy morbidity without a personal history of thrombosis): start low-dose ASA (81 mg/day) before conception or as soon as pregnancy is confirmed, and add prophylactic-dose LMWH once pregnancy is confirmed; continue both throughout pregnancy and through delivery — the combination improves live birth rate and reduces preeclampsia risk compared with ASA alone.[2][5] Thrombotic APS in pregnancy (a personal history of venous or arterial thrombosis): switch from warfarin to therapeutic-dose LMWH before conception if the pregnancy is planned, or immediately on confirmation of an unplanned pregnancy — warfarin crosses the placenta, is teratogenic (fetal warfarin syndrome), and is contraindicated throughout pregnancy, in sharp contrast to its status as the preferred agent for APS-associated thrombosis outside of pregnancy. Continue therapeutic-dose LMWH throughout pregnancy, and resume warfarin (or continue LMWH, per patient preference and specialist input) postpartum. Postpartum: the postpartum period carries the highest VTE risk of the entire pregnancy episode — continue anticoagulation for at least 6 weeks postpartum in every APS pregnancy, including obstetric-only APS, even though prophylactic anticoagulation may not have been used antenatally in that group.[2] Arrange the full peripartum anticoagulation and delivery plan with hematology/rheumatology and obstetric anesthesia well before labour, not on admission.
Breastfeeding
Warfarin, unfractionated heparin, LMWH, and low-dose ASA are all compatible with breastfeeding — warfarin's placental-crossing teratogenicity concern is specific to pregnancy and does not apply postpartum, since only clinically insignificant amounts of warfarin pass into breast milk. A DOAC is not recommended during breastfeeding, independent of the separate reason it is avoided in APS specifically.
Secondary APS (SLE overlap)
Confirm whether SLE or another autoimmune disease coexists at diagnosis, and vice versa (see the Systemic Lupus Erythematosus chapter) — hydroxychloroquine background therapy, SLE-specific monitoring, and shared cardiovascular risk-factor management all apply in addition to the APS-specific anticoagulation plan above; the anticoagulation approach to a given thrombotic or obstetric event does not otherwise differ between primary and secondary APS.
Renal impairment
Dose-reduce LMWH and monitor anti-Xa levels as renal function falls; unfractionated heparin, with no renal clearance dependence, is preferred once impairment is severe. Warfarin dosing is not renally adjusted, but bleeding risk still rises with reduced renal function — monitor INR at least as frequently as usual.
Older adults
Bleeding risk on warfarin rises with age — this is a reason for closer INR monitoring, not a reason to substitute a DOAC in a patient with APS-associated thrombosis.
Perioperative management
Plan warfarin interruption and heparin/LMWH bridging with the treating specialist well in advance of any planned surgery or invasive procedure — do not stop warfarin without a bridging plan in a patient with APS, given the elevated rebound thrombosis risk in this population.
Pediatric APS
Rare in children; refer to pediatric hematology/rheumatology rather than extrapolating adult dosing directly.
Monitoring & Follow-Up
Warfarin: check INR daily or every other day during initiation, then space out to every 2-4 weeks once stable, using the same general schedule as for VTE (see the Venous Thromboembolism chapter); confirm time-in-therapeutic-range at each visit, since a technically "on warfarin" patient with poor time-in-range is a common, correctable cause of apparent treatment failure. LMWH: monitor platelet count for HIT surveillance, particularly in the first 1-2 weeks of exposure; monitor anti-Xa levels in pregnancy and renal impairment. Every patient: reassess bleeding risk against thrombotic risk at every visit rather than assuming a fixed indefinite regimen needs no further review; screen for new or evolving SLE/autoimmune features at least annually; monitor blood pressure, lipids, and glucose given the compounding cardiovascular risk; monitor platelet count periodically, since new or worsening thrombocytopenia can be an early catastrophic-APS warning sign in an acutely unwell patient; in a current or recently pregnant patient, follow the fetal growth/placental-function monitoring schedule set by the obstetric team; and confirm that antibody-positive but not-yet-diagnostic patients are actually brought back for the mandatory 12-week repeat test before a diagnosis is either confirmed or excluded.
Common Errors to Avoid
- Using a DOAC instead of warfarin for APS-associated thrombosis, particularly in triple-positive or arterial disease.
- Diagnosing APS from a single positive antibody test without confirming persistence on a repeat test at least 12 weeks later.
- Ordering lupus anticoagulant testing without accounting for interference from current anticoagulation (heparin, warfarin, or a DOAC).
- Continuing warfarin into a pregnancy instead of switching to LMWH before conception or immediately on confirming an unplanned pregnancy.
- Treating obstetric APS with aspirin alone instead of the combination of low-dose ASA plus prophylactic-dose heparin.
- Stopping postpartum anticoagulation too early - the postpartum period carries the highest VTE risk of the pregnancy episode.
- Missing catastrophic APS in a patient with known APS who develops rapid multi-organ dysfunction, and treating with anticoagulation alone instead of the full combination regimen.
- Continuing estrogen-containing contraception or hormone therapy in an antiphospholipid antibody-positive patient.
- Interrupting warfarin perioperatively without a bridging plan in a patient with APS.
- Withholding anticoagulation in a patient with a genuine thrombotic indication because of mild APS-related thrombocytopenia alone.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment and, in pregnancy, coordination with the obstetric team. Select any drug name to open its complete Pharmasist Drug Database page.
Vitamin K Antagonist (guideline-preferred for APS-associated thrombosis)
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Warfarin | Venous thrombosis: Individualized dose, target INR 2-3, indefinite duration Arterial thrombosis: Individualized dose, target INR 2-3 or 3-4 (individualized), indefinite duration Recurrent thrombosis despite adequate therapy: Consider raising the target to INR 3-4, or adding low-dose ASA, per specialist direction | Bleeding; hair loss and blue/purple toes are uncommon; skin necrosis is rare | Numerous clinically significant interactions - consult a current drug interaction reference before combining any new drug | Overlap with a parenteral anticoagulant for a minimum of 5 days and until the INR is >=2 for 24-48 hours when initiating for a new thrombosis. Monitor INR frequently at initiation, spacing out to every 2-4 weeks once stable. Contraindicated in pregnancy - teratogenic. |
Antiplatelet
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Acetylsalicylic acid (low-dose) | Primary thromboprophylaxis / obstetric APS: 81 mg PO daily Recurrent thrombosis on warfarin (adjunct): 81 mg PO daily, added to warfarin under specialist direction | GI upset, bleeding | Additive bleeding risk with anticoagulants and other antiplatelet agents | Primary thromboprophylaxis in antibody-positive patients without a prior event, and a core component of obstetric APS management combined with heparin. |
Antimalarial (adjunct)
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Hydroxychloroquine | Adjunct: 200-400 mg PO daily | Nausea, cramps, diarrhea, rash, headache, skin hyperpigmentation; rare dose-related retinal toxicity and myopathy | May increase digoxin levels; avoid QT-prolonging agents; concurrent tamoxifen increases retinal toxicity risk; avoid live vaccines during use | Carries an antithrombotic benefit independent of its immunomodulatory effect; particularly considered for triple-positive or SLE-associated APS. Requires scheduled ophthalmologic screening; do not exceed 5 mg/kg/day actual body weight. |
Low Molecular Weight Heparins
Preferred parenteral anticoagulant for obstetric APS and for thrombotic APS during pregnancy - does not cross the placenta, unlike warfarin.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Enoxaparin | Obstetric APS, prophylactic dose: 40 mg SC once daily Thrombotic APS in pregnancy, therapeutic dose: 1 mg/kg SC Q12H | Bleeding; HIT and osteoporosis are both less common than with UFH | Additive bleeding risk with ASA, other antiplatelet agents, and oral anticoagulants | 1 mg = 100 units. Contraindicated with a history of HIT; use with caution in renal dysfunction. |
| Dalteparin | Obstetric APS, prophylactic dose: 5,000 units SC once daily Thrombotic APS in pregnancy, therapeutic dose: 200 units/kg SC once daily, or 100 units/kg SC Q12H if increased bleeding risk | Bleeding; HIT and osteoporosis are both less common than with UFH | Additive bleeding risk with ASA, other antiplatelet agents, and oral anticoagulants | Contraindicated with a history of HIT; use with caution in renal dysfunction. |
| Tinzaparin | Obstetric APS, prophylactic dose: 4,500 units SC once daily Thrombotic APS in pregnancy, therapeutic dose: 175 units/kg SC once daily | Bleeding; HIT and osteoporosis are both less common than with UFH | Additive bleeding risk with ASA, other antiplatelet agents, and oral anticoagulants | Contraindicated with a history of HIT; use with caution in renal dysfunction. |
Unfractionated Heparin
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Heparin (UFH) | IV treatment: 80 units/kg bolus, then 18 units/kg/h infusion adjusted to a therapeutic aPTT | Bleeding, HIT, osteoporosis | Additive bleeding risk with ASA and oral anticoagulants | Preferred over LMWH in severe renal impairment (no renal clearance dependence) and when rapid reversibility is needed, including as a component of catastrophic APS emergency therapy. Monitor platelets closely; contraindicated with a history of HIT. |
Not recommended for APS-associated thrombosis
A randomized trial in high-risk (triple-positive) APS stopped early because rivaroxaban produced significantly more thromboembolic events than warfarin, with no bleeding advantage.<cite data-reference-id="dff1f4d2-db79-4067-8961-5c78114665f2"></cite> Current guidance recommends against a DOAC for APS-associated thrombosis, particularly in triple-positive or arterial disease.<cite data-reference-id="fa95cfc3-c2e1-4771-8e84-3201f11790a6"></cite>
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Rivaroxaban, apixaban, dabigatran, or edoxaban | APS-associated thrombosis: Avoid - use warfarin instead | Higher rate of thrombosis (including stroke and myocardial infarction) than warfarin, in trial evidence specific to APS | Not applicable to this indication - do not substitute for warfarin | Do not use for APS-associated thrombosis, regardless of how effective these agents are for other causes of venous thromboembolism. |
Catastrophic APS - emergency combination therapy
Used together, alongside therapeutic-dose heparin - never as monotherapy - and alongside treatment of any precipitating factor.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Methylprednisolone sodium succinate | Catastrophic APS: 500-1000 mg IV daily for 3 doses, per specialist-directed protocol | Hyperglycemia, mood change, infection risk; more pronounced with pulse dosing | Increased GI ulceration risk with NSAIDs | High-dose pulse therapy is one component of emergency combination therapy for catastrophic APS. |
| Intravenous immunoglobulin (IVIG) | Catastrophic APS: Commonly 0.4 g/kg/day IV for 5 days, or 1 g/kg/day IV for 2 days, per institutional protocol | Infusion reactions, headache, rare thrombosis, rare aseptic meningitis | None significant, though additive thrombosis risk is a theoretical concern in a prothrombotic patient | An alternative or addition to plasma exchange for catastrophic APS, per specialist-directed protocol. |
Warfarin reversal
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Vitamin K1 (phytonadione) | Warfarin reversal, major bleeding: 5-10 mg IV, combined with prothrombin complex concentrate per institutional major-bleeding protocol Warfarin reversal, elevated INR without bleeding: Hold warfarin, +/- low-dose oral vitamin K1, per current INR-management guidance | Rare anaphylactoid reaction with IV administration - give slowly | Antagonizes warfarin's anticoagulant effect | Reduces INR more slowly than prothrombin complex concentrate; combine the two for major bleeding requiring immediate reversal. |
References
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) — Journal of Thrombosis and Haemostasis (Miyakis S, Lockshin MD, Atsumi T, et al.). J Thromb Haemost 2006;4(2):295-306
- EULAR recommendations for the management of antiphospholipid syndrome in adults — Annals of the Rheumatic Diseases, European Alliance of Associations for Rheumatology (Tektonidou MG, Andreoli L, Limper M, et al.). Ann Rheum Dis 2019;78(10):1296-1304
- Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome — Blood, American Society of Hematology (Pengo V, Denas G, Zoppellaro G, et al.). Blood 2018;132(13):1365-1371
- The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria — Arthritis & Rheumatology, American College of Rheumatology / European Alliance of Associations for Rheumatology (Barbhaiya M, Zuily S, Naden R, et al.). Arthritis Rheumatol 2023;75(10):1687-1702
- 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases — Arthritis & Rheumatology, American College of Rheumatology (Sammaritano LR, et al.). Arthritis Rheumatol 2020;72(4):529-556
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.